Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive.

Lamming DW, Ye L, Astle CM, Baur JA, Sabatini DM, Harrison DE.

Aging Cell. 2013 Aug;12(4):712-8. doi: 10.1111/acel.12097. Epub 2013 Jun 7.

2.

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.

Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA.

Science. 2012 Mar 30;335(6076):1638-43. doi: 10.1126/science.1215135.

3.

Chronic rapamycin treatment causes diabetes in male mice.

Schindler CE, Partap U, Patchen BK, Swoap SJ.

Am J Physiol Regul Integr Comp Physiol. 2014 Aug 15;307(4):R434-43. doi: 10.1152/ajpregu.00123.2014. Epub 2014 Jun 25.

4.

Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity.

Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A, Shu YY, Jan YN, Jan LY.

J Mol Med (Berl). 2012 May;90(5):575-85. doi: 10.1007/s00109-011-0834-3. Epub 2011 Nov 22.

5.

Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.

Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M.

Br J Pharmacol. 2012 Apr;165(7):2325-40. doi: 10.1111/j.1476-5381.2011.01716.x.

6.

Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.

Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, Fernandez E, Flurkey K, Javors MA, Nelson JF, Orihuela CJ, Pletcher S, Sharp ZD, Sinclair D, Starnes JW, Wilkinson JE, Nadon NL, Strong R.

J Gerontol A Biol Sci Med Sci. 2011 Feb;66(2):191-201. doi: 10.1093/gerona/glq178. Epub 2010 Oct 25.

7.

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.

Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA.

Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature08221. Epub 2009 Jul 8.

8.

Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.

Houde VP, Brûlé S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, Marette A.

Diabetes. 2010 Jun;59(6):1338-48. doi: 10.2337/db09-1324. Epub 2010 Mar 18.

9.

Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Aging Cell. 2014 Aug;13(4):616-22. doi: 10.1111/acel.12211. Epub 2014 Mar 22.

10.

Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice.

Fok WC, Zhang Y, Salmon AB, Bhattacharya A, Gunda R, Jones D, Ward W, Fisher K, Richardson A, Pérez VI.

J Gerontol A Biol Sci Med Sci. 2013 Feb;68(2):108-16. doi: 10.1093/gerona/gls127. Epub 2012 May 8.

11.

Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.

Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, Javors MA, Li X, Nadon NL, Nelson JF, Pletcher S, Salmon AB, Sharp ZD, Van Roekel S, Winkleman L, Strong R.

Aging Cell. 2014 Jun;13(3):468-77. doi: 10.1111/acel.12194. Epub 2014 Feb 9.

12.

Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver.

Yu Z, Wang R, Fok WC, Coles A, Salmon AB, Pérez VI.

J Gerontol A Biol Sci Med Sci. 2015 Apr;70(4):410-20. doi: 10.1093/gerona/glu053. Epub 2014 Apr 22.

PMID:
24755936
13.

Rapamycin-induced metabolic defects are reversible in both lean and obese mice.

Liu Y, Diaz V, Fernandez E, Strong R, Ye L, Baur JA, Lamming DW, Richardson A, Salmon AB.

Aging (Albany NY). 2014 Sep;6(9):742-54.

14.

Rapamycin extends life and health in C57BL/6 mice.

Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, Diaz V, Sloane L, Maslin K, Treaster S, Réndon S, van Remmen H, Ward W, Javors M, Richardson A, Austad SN, Fischer K.

J Gerontol A Biol Sci Med Sci. 2014 Feb;69(2):119-30. doi: 10.1093/gerona/glt056. Epub 2013 May 16.

15.

Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice.

Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, Hsu HM, Chao TH, Hung SW, Mao FC.

Basic Clin Pharmacol Toxicol. 2009 Sep;105(3):188-98. doi: 10.1111/j.1742-7843.2009.00427.x. Epub 2009 May 26.

16.

PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats.

Festuccia WT, Blanchard PG, Belchior T, Chimin P, Paschoal VA, Magdalon J, Hirabara SM, Simões D, St-Pierre P, Carpinelli A, Marette A, Deshaies Y.

Am J Physiol Endocrinol Metab. 2014 May 1;306(9):E1046-54. doi: 10.1152/ajpendo.00683.2013. Epub 2014 Mar 11.

17.

Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.

Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV.

Cell Cycle. 2011 Dec 15;10(24):4230-6. doi: 10.4161/cc.10.24.18486. Epub 2011 Dec 15.

PMID:
22107964
18.
19.

Hormone levels and cataract scores as sex-specific, mid-life predictors of longevity in genetically heterogeneous mice.

Harper JM, Wolf N, Galecki AT, Pinkosky SL, Miller RA.

Mech Ageing Dev. 2003 Jul;124(7):801-10.

PMID:
12875743
20.

Partial ablation of adult Drosophila insulin-producing neurons modulates glucose homeostasis and extends life span without insulin resistance.

Haselton A, Sharmin E, Schrader J, Sah M, Poon P, Fridell YW.

Cell Cycle. 2010 Aug 1;9(15):3063-71. doi: 10.4161/cc.9.15.12458. Epub 2010 Aug 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk